Taikang Insurance Group Company

Singularity Cloud is a tech company focused on using big data and AI technology to enhance the business capabilities of enterprises.

ClinChoice Kunling was established in Tianjin inSince its establishment, through its own organic growth and strategic mergers and acquisitions, ClinChoice has more than 3,000 clinical R&D professionals around the world, located in hot cities and regions of domestic and foreign pharmaceutical R&D, and has developed into a local clinical CRO enterprise model supporting innovative drug device R&D. . The company adheres to the connotation of "Kunxing Zhiyuan · Ling creates the future", which means to become an ideal partner for the clinical research and development of innovative pharmaceutical devices.

UINO specializes in real-time digital twin visualization software that enables the management of digital infrastructures. By integrating digital twin technology with advanced visualization tools, the company creates comprehensive digital representations of physical objects. This technology allows users to simulate, monitor, analyze, and control real-world items, effectively bridging the logical and physical worlds within a digital framework. UINO's offerings include a smart visual management platform and a suite of development tools, such as a 3D engine, SDK, and various editors for creating digital twin solutions tailored to diverse applications. The company has secured significant venture funding to enhance its research and development efforts, supporting its mission to improve understanding and management of physical environments through innovative digital solutions.

XISOFT is a professional manufacturer specializing in informatization and data services within health economic management. The company develops an enterprise resource planning (ERP) platform tailored for hospitals, providing comprehensive management and monitoring capabilities across various functions, including finance, supply chain, human resources, and diagnosis-related groups. By leveraging technology, XISOFT aims to support medical institutions in streamlining operations and enhancing efficiency. Its platform enables effective business integration and refined management, addressing key areas such as intelligent finance, material assets, internal control, and event management. Through its innovative solutions, XISOFT assists healthcare providers in realizing their strategic objectives and improving overall operational effectiveness.

Hong Kong Asia Heart Centre is a cardiovascular specialist chain that provides various cardiovascular assessment and surgical services. Founded in 1999, The Hong Kong Asian Heart Center has a professional medical team with many years of experience in the treatment of heart disease.

ForwardX Robotics, Inc. is a technology developer specializing in artificial intelligence and mobile robotics, founded in 2016 and headquartered in Beijing, China, with additional offices in San Diego and Phoenix. The company has a robust team of over 250 employees, including 120 engineers, and holds more than 200 pending patents. ForwardX is known for its innovative products, such as a side-follow suitcase equipped with GPS and 3G technology, allowing users to track their belongings via a dedicated application named Ovis. The suitcase features a removable battery and human-centric design. In addition to consumer products, ForwardX develops Autonomous Mobile Robots and Fleet Management solutions aimed at addressing significant challenges in logistics and manufacturing, such as rising labor costs, inefficient processes, and safety concerns. The company's robotics systems are designed to perceive their environment and adapt to dynamic circumstances, providing users with enhanced autonomy, flexibility, and productivity.

Singularity Cloud is a tech company focused on using big data and AI technology to enhance the business capabilities of enterprises.

Star Charge specializes in the development and manufacturing of charging equipment specifically for new energy vehicles. The company serves a global clientele by providing comprehensive charging infrastructures, platforms, and data operations, leveraging Internet of Things technologies. Star Charge's offerings encompass various aspects of electric vehicle support, including vehicle sales, private and public charging solutions, and financial services. By focusing on these areas, the company aims to enhance energy efficiency, facilitate structural adjustments in energy utilization, promote energy conservation, and mitigate pollution emissions.

Xingyun Group specializes in transforming the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company employs whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine integrates industrial ecological resources, facilitating cost reduction and efficiency improvements through data utilization. Xingyun Group supports overseas consumer brands in entering the Chinese market while assisting Chinese brands in their global expansion efforts. The platform boasts nearly 160 cooperative and self-operated warehouses across 72 countries and one region, catering to over 350,000 online and offline retailers in China. Its product offerings include maternal and child supplies, beauty care, healthcare, digital products, clothing, and shoes, ensuring reliable and cost-effective purchasing solutions for domestic retailers.

Jihu Information Technology (Hubei) Co., Ltd. is referred to as GitLab, adhering to the "Open-core" principle, combining the world's leading DevOps technology with localized self-developed innovation and customized services, is committed to serving Chinese users. Provide a one-stop open and integrated DevOps platform covering the software development life cycle. Jihu GitLab owns the exclusive intellectual property rights and brand authorization of GitLab, Inc. It is updated monthly based on the GitLab EE version, and on this basis, we add our customized features for domestic users. JiHu GitLab is an out-of-the-box, open DevOps platform built from the ground up as a single application for all stages of the DevOps lifecycle enabling Product, Development, QA, Security, and Operations teams to work concurrently on the same project. JiHu GitLab provides a single data store, one user interface, and one permission model across the DevOps lifecycle, accelerating software development lifecycle through industry-leading project management, security, and compliance features. JiHu GitLab is independently developed and operated in China by GitLab Information Technology (Hubei) Co., Ltd. Investors include GitLab Inc., Sequoia CBC and Gaocheng Capital.

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

Xingyun Group specializes in transforming the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company employs whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine integrates industrial ecological resources, facilitating cost reduction and efficiency improvements through data utilization. Xingyun Group supports overseas consumer brands in entering the Chinese market while assisting Chinese brands in their global expansion efforts. The platform boasts nearly 160 cooperative and self-operated warehouses across 72 countries and one region, catering to over 350,000 online and offline retailers in China. Its product offerings include maternal and child supplies, beauty care, healthcare, digital products, clothing, and shoes, ensuring reliable and cost-effective purchasing solutions for domestic retailers.

Zongteng Network, established in November 2007 in Fuzhou, China, is a leading global provider of cross-border e-commerce infrastructure services. With a workforce exceeding 1,000 employees, the company plays a pivotal role in the cross-border e-commerce sector by integrating various functions such as product development, procurement, sales, warehousing, logistics, customer service, and system research and development. Zongteng operates on both third-party e-commerce platforms, including eBay, Amazon, and Alibaba, and through its own B2C mall, enhancing its import capabilities. The company specializes in offering comprehensive logistics solutions, including overseas warehousing and international shipping, aimed at assisting international e-commerce businesses in establishing efficient logistics and distribution networks.

Guoke Hengtai (Beijing) Medical Technology Co., Ltd., established in February 2013, is a company based in the Yizhuang Economic and Technological Development Zone of Beijing. It operates under the umbrella of Oriental Science and Technology Holding Group Co., Ltd., a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. The company specializes in the distribution and direct sales of medical devices, offering a range of professional services, including warehousing logistics, distribution channel management, and hospital SPD operation management. Since its inception, Guoke Hengtai has experienced significant growth, achieving a compound annual growth rate exceeding 50% over four years and embarking on an initial public offering journey in 2017.

Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

Transcenta Holding Ltd. is a clinical-stage biotherapeutics company focused on the research, development, and manufacturing of antibody-based therapeutics. Established in 2019 and headquartered in Suzhou, China, the company operates additional facilities in Shanghai, Hangzhou, Beijing, Waltham, and Princeton. Transcenta's integrated approach encompasses the discovery and development of innovative antibodies aimed at addressing various medical conditions, particularly in oncology and specific non-oncology areas such as bone and kidney disorders. The company is currently advancing nine therapeutic antibody molecules through clinical development, underscoring its commitment to improving patient outcomes. Transcenta was formed through the merger of HJB and MabSpace Biosciences, positioning it as a significant player in the global biopharmaceutical landscape.

Taikang Bybo Medical Group is a national dental medical group with a large-scale operation. It is dedicated to providing high-quality full-lifecycle oral medical services for middle and upper-income people, pursuing the ultimate customer experience, investigating the "Caesar model" in the field of domestic oral medical services, and constructing China's largest and best high-end dental chain brand.

CStone Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing innovative immuno-oncology and molecularly targeted drugs aimed at addressing significant unmet medical needs in cancer treatment. Founded in 2015 and headquartered in Shanghai, China, the company has established a robust product pipeline that includes several late-stage clinical candidates, such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, which targets programmed death receptor. Other notable products include ivosidenib, avapritinib, and pralsetinib, along with a variety of additional investigational drugs for solid tumors and other cancer indications. CStone engages in strategic collaborations, including a licensing agreement with Numab Therapeutics for a tri-specific antibody and a clinical partnership with Bayer HealthCare to assess the efficacy of CS1001 in combination therapies. The company aims to enhance treatment options for cancer patients both in China and globally through its dedicated research and development efforts.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Easyhome is a prominent home improvement and furniture retail chain in China, operating 223 stores across 29 provinces, making it the second largest in its sector. The company is involved in various aspects of retail, including the development of commercial properties, shopping mall decoration, and an e-commerce platform. In addition to its home furnishing stores, Easyhome manages department stores, shopping malls, discount supermarkets, and hypermarkets. The firm also engages in shop leasing and project development, contributing to its diverse business portfolio. Through its extensive network and operations, Easyhome aims to meet the growing demand for home improvement products and services in the Chinese market.

EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

MXB Biotechnologies is a company that develops immunohistochemical diagnostic reagents for tumor pathology. The scope of the company includes molecular pathological diagnosis, precision medical diagnostics, immunocytochemistry diagnosis, and tumor pathological diagnosis. The items are utilized for clinical diagnostics and pathology department diagnosis.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Womai is a B2C online grocery shopping platform in China, established in 2008 by COFCO Corporation, a prominent supplier of agricultural products and food. The platform focuses on providing customers with convenient access to a variety of healthy food options and essential grocery items, catering to daily household needs. By facilitating online shopping, Womai aims to save customers time while promoting the consumption of nutritious foods. The company is committed to leveraging renewable natural resources to enhance the quality of life and contribute positively to society.

BGI is a biotechnology company specializing in genomics, providing genome sequencing and genetic testing services to research institutions and healthcare professionals. Operating through its subsidiary, Shenzhen Huada Gene Technology Co. Ltd., BGI offers a wide range of services including bioinformatics testing, agricultural genomics research, and proteomics research. The company collaborates with various organizations to enhance research efforts in the pharmaceutical and healthcare sectors. BGI also supplies products such as DNA extraction kits and other related tools, positioning itself as a key player in advancing genetic and genomic research.